5 completed, 3 withdrawn, 1 terminated. 7 Phase 2, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Withdrawn 2, Terminated 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Cannabinoids: new trials by email Literature Review of Cannabinoids trials Research Report on Cannabinoids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Measuring Acute Drug Demand in Humans II Blinded Study Medication - Condition 1, Blinded Study Medication - Condition 2, Blinded Study Medication - Condition 3 - Healthy Volunteers | Early Phase 1 | Withdrawn | Johns Hopkins University | 2025-11-15 | 2025-11-12 | |
| Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy PO BRC-003 (High Cannabidiol Cannabis Extract), Placebo - Post-traumatic Epilepsy | Phase 2 | Withdrawn | Dr. Paul Lyons | 2024-11-01 | 2025-04-24 | |
| Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control oral cannabinoid, oral codeine/acetaminophen - Photorefractive Keratectomy, Myopia | Phase 2 | Completed | University of Florida | 35 | 2024-02-01 | 2025-08-07 |
| Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption - Sleep Disorder, Healthy | Phase 2 | Completed | Johns Hopkins University | 148 | 2020-11-11 | 2025-09-24 |
| Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region CBD Oil, Hemp Oil - TMJ Disorder, Myofacial Pain | Not applicable | Completed | Weill Medical College of Cornell University | 59 | 2020-08-06 | 2023-03-14 |
| Cannabinoids for Taxane Induced Peripheral Neuropathy Cannabinoids - Chemotherapy-induced Peripheral Neuropathy | Phase 2 | Terminated | New York State Psychiatric Institute | 12 | 2019-09-01 | 2023-01-26 |
| Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease Cannabidiol, Placebo oral capsule - Crohn Disease, Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Withdrawn | University of Illinois at Chicago | 2018-07-01 | 2020-03-25 | |
| Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis Blinded study medication - Knee Osteoarthritis | Phase 2 | Completed | Johns Hopkins University | 58 | 2017-11-01 | 2024-12-11 |
| Cannabinoids for Behavioral Problems in Children With ASD Cannabinoids - 99% pure cannabinoids mix, Placebo, Cannabinoids - whole plant extract - Autistic Disorder | Phase 2 | Completed | Shaare Zedek Medical Center | 150 | 2017-01-01 | 2018-12-27 |
Agnosia (1) · Autistic Disorder (1) · Crohn Disease (1) · Epilepsy, Post-Traumatic (1) · Facial Pain (1) · Hyperopia (1) · Inflammatory Bowel Diseases (1) · Marijuana Abuse (1) · Myopia (1) · Osteoarthritis, Knee (1) · Pain (1) · Parasomnias (1) · Sleep Apnea Syndromes (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1)
Johns Hopkins University (3) · Dr. Paul Lyons (1) · New York State Psychiatric Institute (1) · Shaare Zedek Medical Center (1) · University of Florida (1) · University of Illinois at Chicago (1) · Weill Medical College of Cornell University (1)
United States (7) · Israel (1)
Adi Aran, MD (1) · Alexandra Kearson, BA (1) · Claudia Campbell, PhD (1) · Claudia M Campbell, Ph.D. (1) · Eric C Strain, MD (1) · Gwendolyn Reeve, DMD FACS (1) · Hiroto Kuwabara, MD (1) · Jeannie Leoutsakos, PhD (1) · Justin Stricklahd, PhD (1) · Kelly E Dunn, Ph.D. (1) · Michael T Smith, PhD (1) · Naresh Punjabi, MD (1) · Patrick H Finan, PhD (1) · Paul D Lyons, MD. PhD (1) · Varda Gross (1)
PMID 33536055, PMID 40611810, PMID 41481837, PMID 42524865
R01DA042751 (1), U01HL150568 (1)